EWL Stock Overview
Provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for EWL from our risk checks.
Edwards Lifesciences Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$67.00 |
| 52 Week High | US$88.92 |
| 52 Week Low | US$54.00 |
| Beta | 1.12 |
| 11 Month Change | 7.22% |
| 3 Month Change | 5.85% |
| 1 Year Change | 9.69% |
| 33 Year Change | -31.20% |
| 5 Year Change | -9.78% |
| Change since IPO | 4,802.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| EWL | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 7.9% | -1.0% | -0.02% |
| 1Y | 9.7% | -7.3% | 8.2% |
Return vs Industry: EWL exceeded the German Medical Equipment industry which returned -7.3% over the past year.
Return vs Market: EWL exceeded the German Market which returned 8.2% over the past year.
Price Volatility
| EWL volatility | |
|---|---|
| EWL Average Weekly Movement | 4.0% |
| Medical Equipment Industry Average Movement | 5.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: EWL has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: EWL's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1958 | 19,800 | Bernard Zovighian | www.edwards.com |
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve.
Edwards Lifesciences Corporation Fundamentals Summary
| EWL fundamental statistics | |
|---|---|
| Market cap | €39.92b |
| Earnings (TTM) | €1.51b |
| Revenue (TTM) | €6.06b |
26.5x
P/E Ratio6.6x
P/S RatioIs EWL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EWL income statement (TTM) | |
|---|---|
| Revenue | US$6.31b |
| Cost of Revenue | US$1.48b |
| Gross Profit | US$4.84b |
| Other Expenses | US$3.27b |
| Earnings | US$1.57b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.66 |
| Gross Margin | 76.60% |
| Net Profit Margin | 24.82% |
| Debt/Equity Ratio | 6.2% |
How did EWL perform over the long term?
See historical performance and comparison